Three studies separate weight regain after stopping from two active maintenance strategies

What happened

Three 2026 reports addressed what can happen after medication-assisted weight reduction, but they did not test one shared strategy. A BMJ review estimated weight regain after weight-management medicines stopped. ATTAIN-MAINTAIN evaluated switching from injectable tirzepatide or semaglutide to oral orforglipron. SURMOUNT-MAINTAIN compared continued, reduced-dose, and withdrawn tirzepatide.

BMJ review: outcomes after medication cessation

The systematic review combined 37 studies with 9,341 participants. Across all weight-management medicines, average regain after treatment ended was estimated at 0.4 kilograms per month. The model projected a return to pretreatment weight at about 1.7 years. In randomized comparisons, the average difference between prior-treatment and control groups was no longer apparent about 1.4 years after cessation.

Results were less certain for newer incretin medicines because post-treatment observation was limited. The model estimated 9.9 kilograms of regain during the first year after newer incretin therapy and a return to baseline at about 1.5 years. Those figures are pooled projections, not a schedule for each patient. Studies differed in medicine, initial loss, treatment duration, follow-up, and post-treatment support.

ATTAIN-MAINTAIN: switching to oral orforglipron

This phase 3b trial enrolled 376 U.S. participants after 72 weeks in SURMOUNT-5. One cohort had used tirzepatide and the other semaglutide. Within each cohort, participants were randomized to once-daily orforglipron or placebo for 52 weeks.

After prior tirzepatide, the orforglipron group maintained an estimated 74.7% of its earlier weight reduction, compared with 49.2% in the placebo group. After prior semaglutide, the corresponding estimates were 79.3% and 37.6%. This trial tested a switch to a specific oral medicine. It did not compare switching with staying on the original injection.

SURMOUNT-MAINTAIN: continuing or reducing tirzepatide

In this separate phase 3b study, 378 participants who had completed 60 weeks of open-label tirzepatide were assigned to continue their maximum tolerated 10 mg or 15 mg dose, reduce to 5 mg, or change to placebo for another 52 weeks.

By week 112, the maximum-dose group remained 21.9% below its original weight on average. Reductions were 16.6% on 5 mg and 9.9% following the placebo switch. Rescue tirzepatide was used by 8%, 25%, and 67% of the respective groups after substantial regain.

What it means

The reports make three distinct points. Weight often moved back toward baseline after medicines ended in prior studies. Switching to orforglipron preserved more prior reduction than switching to placebo in ATTAIN-MAINTAIN. Continuing tirzepatide, including at 5 mg, preserved more than withdrawal in SURMOUNT-MAINTAIN.

That distinction matters because cessation, substitution, and dose reduction are different clinical decisions. Evidence for one medicine and protocol cannot establish the best maintenance plan for another.

What it does not mean

The BMJ timelines are model projections from pooled studies, not deadlines by which every participant regained all weight. The two randomized trials selected people who completed substantial initial treatment, so their averages may not apply to those who stop early because of side effects, cost, limited response, pregnancy, another illness, or access problems.

ATTAIN-MAINTAIN does not show that orforglipron is equivalent to continuing tirzepatide or semaglutide because it did not include those continuation groups. SURMOUNT-MAINTAIN does not establish that 5 mg is sufficient for every patient or every clinical goal.

None of the studies is a self-directed tapering guide. A maintenance decision can involve weight trajectory, metabolic health, adverse effects, affordability, preferences, and whether another treatment is available.